433 related articles for article (PubMed ID: 36932369)
1. Study protocol for an efficacy trial of the "PrEP for Health" intervention to increase HIV PrEP use among people who inject drugs.
Bazzi AR; Bordeu M; Baumgartner K; Sproesser DM; Bositis CM; Krakower DS; Mimiaga MJ; Biello KB
BMC Public Health; 2023 Mar; 23(1):513. PubMed ID: 36932369
[TBL] [Abstract][Full Text] [Related]
2. Study protocol of a randomized controlled trial to assess the efficacy of the "PrEPare for Work" intervention to enhance PrEP uptake and optimize adherence for HIV prevention among male sex workers in the U.S.
Biello KB; Chan PA; Ndoye CD; Nelson L; Nelson E; Silva V; Kwak E; Napoleon S; Cormack Orellana C; Richards OG; Davis E; Mimiaga MJ
BMC Public Health; 2024 Feb; 24(1):424. PubMed ID: 38336731
[TBL] [Abstract][Full Text] [Related]
3. Systematic review of HIV treatment adherence research among people who inject drugs in the United States and Canada: evidence to inform pre-exposure prophylaxis (PrEP) adherence interventions.
Bazzi AR; Drainoni ML; Biancarelli DL; Hartman JJ; Mimiaga MJ; Mayer KH; Biello KB
BMC Public Health; 2019 Jan; 19(1):31. PubMed ID: 30621657
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs.
Biello KB; Bazzi AR; Mimiaga MJ; Biancarelli DL; Edeza A; Salhaney P; Childs E; Drainoni ML
Harm Reduct J; 2018 Nov; 15(1):55. PubMed ID: 30419926
[TBL] [Abstract][Full Text] [Related]
5. Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.
Bartholomew TS; Plesons M; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; Chueng TA; Ciraldo K; Brooks J; Smith JD; Barocas JA; Tookes HE
Addict Sci Clin Pract; 2024 Mar; 19(1):21. PubMed ID: 38528570
[TBL] [Abstract][Full Text] [Related]
6. M
Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
[TBL] [Abstract][Full Text] [Related]
7. Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
McKellar MS; Des Marais AC; Chen H; Choi Y; Lilly R; Ayers D; Bennett J; Kestner L; Perry B; Poley S; Corneli A; Meade CS; Sachdeva N
Harm Reduct J; 2024 Mar; 21(1):69. PubMed ID: 38532395
[TBL] [Abstract][Full Text] [Related]
8. Limited Knowledge and Mixed Interest in Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs.
Bazzi AR; Biancarelli DL; Childs E; Drainoni ML; Edeza A; Salhaney P; Mimiaga MJ; Biello KB
AIDS Patient Care STDS; 2018 Dec; 32(12):529-537. PubMed ID: 30311777
[TBL] [Abstract][Full Text] [Related]
9. Pre-Exposure Prophylaxis Barriers, Facilitators and Unmet Need Among Rural People Who Inject Drugs: A Qualitative Examination of Syringe Service Program Client Perspectives.
Surratt HL; Yeager HJ; Adu A; González EA; Nelson EO; Walker T
Front Psychiatry; 2022; 13():905314. PubMed ID: 35706473
[TBL] [Abstract][Full Text] [Related]
10. Qualitative inquiry into perceptions of HIV pre-exposure prophylaxis among people who inject drugs living with hepatitis C in Seattle, WA, USA.
Barry MP; Austin EJ; Bhatraju EP; Glick SN; Stekler JD; Tung EL; Hansen RN; Williams EC; Gojic AJ; Pickering EI; Tsui JI
Harm Reduct J; 2022 Nov; 19(1):121. PubMed ID: 36320005
[TBL] [Abstract][Full Text] [Related]
11. Contingency Management and Pre-Exposure Prophylaxis Adherence Support Services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs.
Sung ML; Viera A; Esserman D; Tong G; Davidson D; Aiudi S; Bailey GL; Buchanan AL; Buchelli M; Jenkins M; John B; Kolakowski J; Lame A; Murphy SM; Porter E; Simone L; Paris M; Rash CJ; Edelman EJ
Contemp Clin Trials; 2023 Feb; 125():107037. PubMed ID: 36460267
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an inner city HIV pre-exposure prophylaxis service tailored to the needs of people who inject drugs.
Grimshaw C; Boyd L; Smith M; Estcourt CS; Metcalfe R
HIV Med; 2021 Nov; 22(10):965-970. PubMed ID: 34585494
[TBL] [Abstract][Full Text] [Related]
13. Linking women experiencing incarceration to community-based HIV pre-exposure prophylaxis care: protocol of a pilot trial.
Ramsey SE; Ames EG; Brinkley-Rubinstein L; Teitelman AM; Clarke J; Kaplan C
Addict Sci Clin Pract; 2019 Mar; 14(1):8. PubMed ID: 30832717
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study.
Shrestha R; Altice FL; Sibilio B; Ssenyonjo J; Copenhaver MM
Contemp Clin Trials; 2019 Jul; 82():77-84. PubMed ID: 31229618
[TBL] [Abstract][Full Text] [Related]
15. Brief Report: Use of Pre-Exposure Prophylaxis to Prevent Rapid HIV Transmission Among People Who Inject Drugs in Rural Counties in the United States: A Modeling Study.
Jacka BP; Nolen S; Bessey SE; Zang X; Goedel WC; Yedinak JL; Marshall BDL
J Acquir Immune Defic Syndr; 2022 Dec; 91(5):449-452. PubMed ID: 36150038
[TBL] [Abstract][Full Text] [Related]
16. Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study).
Goodman-Meza D; Shoptaw S; Hanscom B; Smith LR; Andrew P; Kuo I; Lake JE; Metzger D; Morrison EAB; Cummings M; Fogel JM; Richardson P; Harris J; Heitner J; Stansfield S; El-Bassel N;
Trials; 2024 Feb; 25(1):124. PubMed ID: 38360750
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Patient and Provider Perspectives on a Novel, Low-Threshold HIV PrEP Program for People Who Inject Drugs Experiencing Homelessness.
Bazzi AR; Shaw LC; Biello KB; Vahey S; Brody JK
J Gen Intern Med; 2023 Mar; 38(4):913-921. PubMed ID: 35614171
[TBL] [Abstract][Full Text] [Related]
19. The role of syringe exchange programs and sexual identity in awareness of pre-exposure prophylaxis (PrEP) for male persons who inject drugs.
Walters SM; Coston B; Neaigus A; Rivera AV; Starbuck L; Ramirez V; Reilly KH; Braunstein SL
Int J Drug Policy; 2020 Mar; 77():102671. PubMed ID: 32092665
[TBL] [Abstract][Full Text] [Related]
20. Preliminary Efficacy of a Theory-Informed Intervention to Increase COVID-19 Testing Uptake Among People Who Inject Drugs in San Diego County: Findings From a Pilot Randomized Controlled Trial.
Bazzi AR; Abramovitz D; Harvey-Vera A; Stamos-Buesig T; Vera CF; Artamonova I; Logan J; Patterson TL; Strathdee SA
Ann Behav Med; 2023 May; 57(6):472-482. PubMed ID: 37029714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
